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Regulation of Ubiquitin Specific Peptidase 2 (USP2) by the Farnesoid X Receptor (FXR) in
Hepatocellular Carcinoma
Doris W. Lee
The farnesoid X receptor (FXR) signaling pathways have been established to be involved in the
pathogenesis of hepatocellular carcinoma (HCC) in prior studies and one proposed mechanism
may be through regulation of the ubiquitin specific peptidase 2 (USP2) gene. As the mechanism
has yet to be defined, more research is needed to identify the role of FXR and USP2 in HCC
development. This study investigated the effects of FXR signaling activation on the
transcriptional expression of USP2 promoter and explored their potential role in the
pathogenesis of HCC. The first objective was to investigate the expression of USP2 in human
hepatocellular carcinoma cells (HepG2) by looking at the circadian endogenous USP2
expression and then treating cells with FXR agonists and antagonists. The second objective
was to characterize regulation of the USP2 promoter by transfecting cells with FXR and USP2
promoter, followed by looking at the USP2 promoter activity. The effects of treatments with FXR
agonists and FXR antagonists on USP2 promoter activities were then examined. Findings from
this study will provide a better understanding of the potential mechanism into development of
HCC and be the basis for future research.

